GLAXOSMITHKLINE, LLC: $81.3M Department of Health and Human Services Contract Vehicle
Summary
The CDC awarded $81.3M to GlaxoSmithKline, LLC for pediatric flu vaccines. Since the recipient is a private entity, no publicly traded companies directly benefit from this contract.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The recipient is private, so no public company is directly impacted.
- 2.The contract supports pediatric flu vaccine supply but is not a market-moving event.
- 3.Investors should not infer benefits to competitors or supply chain partners without concrete evidence.
Market Implications
Given that GlaxoSmithKline, LLC is private, there are no direct market implications for publicly traded companies. The broader vaccine sector may see indirect sentiment from continued government spending on flu prevention, but no specific company can be tied to this award. Retail investors should not adjust positions based on this contract.
Full Analysis
The Department of Health and Human Services, through the Centers for Disease Control and Prevention, awarded an indefinite delivery/indefinite quantity contract worth $81.3M to GlaxoSmithKline, LLC for pediatric flu vaccines. The contract runs from December 2025 through February 2027. GlaxoSmithKline, LLC is a private entity and not a publicly traded company or recognized subsidiary, so this contract does not directly flow to any public company. While vaccine spending generally supports the broader healthcare sector, no specific public ticker can be attributed without introducing false positives. The contract is a routine public health procurement and does not signal a shift in sector dynamics. No related legislation directly connects to this award, as the relevant bill signals in the database lack specific funding or policy mechanisms for pediatric flu vaccines.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
MERCK SHARP & DOHME LLC: $2.4B Department of Health and Human Services Contract Vehicle
ASCEND AEROSPACE AND TECHNOLOGY, LLC: $22.8M National Aeronautics and Space Administration Contract Vehicle
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
To Facilitate Positive Adjustment to Competition from Imports of Quartz Surface Products
This proclamation imposes a 4-year tariff-rate quota on imports of quartz surface products (QSP) to protect the domestic industry from serious injury caused by increased imports. It excludes Canada, Mexico, Australia, CAFTA-DR countries, Colombia, Israel, Jordan, Korea, Panama, Peru, Singapore, and CBERA beneficiaries, and provides a developing-country exemption. The action is a safeguard measure under section 202 of the Trade Act of 1974.
Presidential Determination Pursuant to Section 101 of the Defense Production Act of 1950, as Amended, on Recoverable Critical Minerals and Materials
This memorandum invokes the Defense Production Act (DPA) Section 101 to declare that recoverable critical minerals and materials (such as black mass, end-of-life rare-earth magnets, and scrap) are essential to national defense and that the U.S. cannot meet defense needs without disrupting civilian markets. It directs the Secretary of Commerce to issue regulations and take actions—including priority contracts and supply-chain interventions—to rapidly expand domestic recovery and processing of these materials, while explicitly excluding copper scrap already covered by a separate proclamation.
Actions by the United States in the Investigations under Section 301 of the Trade Act of 1974 of the Acts, Policies, and Practices of 60 Economies Related to the Failure of Each Economy to Impose and Effectively Enforce a Prohibition on the Importation of Goods Produced with Forced Labor
This Presidential Memorandum directs the U.S. Trade Representative to impose Section 301 tariffs on imports from 60 economies due to their failure to prohibit or effectively enforce forced labor import bans. Tariffs are set at 10% ad valorem for certain economies with partial enforcement or commitments, and 12.5% for others, with exemptions for raw materials and products causing domestic supply issues, and plans for textile tariff-rate quotas by September 2026. The action aims to eliminate the identified unreasonable trade practices through these tariffs and incentives.
Contract Details
Recipient
GLAXOSMITHKLINE, LLC
Award Amount
$81,300,001
Awarding Agency
Department of Health and Human Services
Sub-Agency
Centers for Disease Control and Prevention
Contract Type
INDEFINITE DELIVERY / INDEFINITE QUANTITY
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →